The underlying idea of using placental antigens as effective cancer vaccines led to our recent observation that immunization with placenta-specific 1 (PLAC1), a membrane-associated protein, delays tumor onset and increases survival in a mouse model of melanoma. Here, PLAC1 is linked to cancer.